Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER progr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Philippe A. Cassier, Clémentine Peyramaure, Valery Attignon, Lauriane Eberst, Camille Pacaud, Sandrine Boyault, Françoise Desseigne, Mathieu Sarabi, Pierre Guibert, Pauline Rochefort, Nathalie Marques, Michel Rivoire, Aurélien Dupré, Patrice Peyrat, Catherine Terret, Isabelle Ray-Coquard, Clélia Coutzac, David Pérol, Jean-Yves Blay, Olivier Trédan, Christelle de la Fouchardière
Format: article
Langue:EN
Publié: Elsevier 2022
Sujets:
Oesophageal cancer
Gastric cancer
Molecular alterations, molecular-targeted agents
NGS
CGH
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700

Documents similaires